Oncobit develops CE certified, highly sensitive tests for diagnosis, treatment selection and monitoring of cancer patients. We are addressing the rapidly expanding market of precision oncology and personalized disease monitoring using non-invasive technologies. Our founding team consists of professionals with deep expertise in oncology, bioinformatics, software development, and management. We are based in Zurich and hold an exclusive technology license from the University of Zurich.

“Within a project supported by @Innosuisse, we are developing sensitive tests for monitoring cancer patients. We are now considering reusing the technology for a covid19 test.”

Seline Eisenring, CEO